Generic firms could face hurdles in showing that their opioid products have abuse deterrence properties comparable to the innovator product, stakeholders suggest in response to FDA's draft guidance.
Edward Cone, principal scientist, drug delivery and abuse-deterrent drug products at PinneyAssociates, said the agency's call for generic companies to...